EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study

Anna Mizielska, Iga Dziechciowska, Radosław Szczepański, Małgorzata Cisek, Małgorzata Dąbrowska, Jan Ślężak, Izabela Kosmalska, Marta Rymarczyk, Klaudia Wilkowska, Barbara Jacczak, Ewa Totoń iD, Natalia Lisiak und 2 weitere

Genes · 12.03.2023 · 14 (3) · 702

DOI: 10.3390/genes14030702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 12.03.2023. Verfasst von Anna Mizielska und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minister of Science and Higher Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the most innovative medical trends is personalized therapy, based on simple and reproducible methods that detect unique features of cancer cells. One of the good prognostic and diagnostic markers may be the miRNA family. Our work aimed to evaluate changes in selected miRNA levels in various breast cancer cell lines (MCF7, MDA-MB-231, SK-BR-3) treated with doxorubicin or cisplatin. The selection was based on literature data regarding the most commonly altered miRNAs in breast cancer (21-3p, 21-5p, 106a-5p, 126-3p, 126-5p, 155-3p, 155-5p, 199b-3p, 199b-5p, 335-3p, 335-5p). qPCR assessment revealed significant differences in the basal levels of some miRNAs in respective cell lines, with the most striking difference in miR-106a-5p, miR-335-5p and miR-335-3p—all of them were lowest in MCF7, while miR-153p was not detected in SK-BR-3. Additionally, different alterations of selected miRNAs were observed depending on the cell line and the drug. However, regardless of these variables, 21-3p/-5p, 106a, 126-3p, 155-3p and 199b-3p miRNAs were shown to respond either to doxorubicin or to cisplatin treatment. These miRNAs seem to be good candidates for markers of breast cancer cell response to doxorubicin or cisplatin. Especially since some earlier reports suggested their role in affecting pathways and expression of genes associated with the DNA-damage response. However, it must be emphasized that the preliminary study shows effects that may be highly related to the applied drug itself and its concentration. Thus, further examination, including human samples, is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMicroRNAsHumansFemaleCisplatinDoxorubicinMCF-7 CellsDNA

Stichwörter der Autor:innen

breast cancerdiagnosticsmiRNAtherapy response

Substanzen

CisplatinMicroRNAsDoxorubicinDNAMIRN106 microRNA, humanMIRN126 microRNA, humanMIRN155 microRNA, humanmirn199 microRNA, humanMIRN21 microRNA, human

Autor:innen und Institutionen

  • Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
  • Centre for Orthodontic Mini-Implants, Department and Clinic of Maxillofacial Orthopedics and Orthodontics, Poznan University of Medical Sciences, Bukowska 70, 60-812 Poznan, Poland.

ORCID-Profile: Ewa Totoń, Błażej Rubiś

Förderung

  • Minister of Science and Higher Education

Zitieren

APA

Mizielska, A., Dziechciowska, I., Szczepański, R., Cisek, M., Dąbrowska, M., Ślężak, J., Kosmalska, I., Rymarczyk, M., Wilkowska, K., Jacczak, B., Totoń, E., Lisiak, N., Kopczyński, P., & Rubiś, B. (2023). Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study. Genes, 14(3), 702. https://doi.org/10.3390/genes14030702

Vancouver

Mizielska A, Dziechciowska I, Szczepański R, Cisek M, Dąbrowska M, Ślężak J, et al. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study. Genes. 2023;14(3):702. doi:10.3390/genes14030702

BibTeX
@article{Mizielska2023,
  author = {Mizielska, Anna and Dziechciowska, Iga and Szczepański, Radosław and Cisek, Małgorzata and Dąbrowska, Małgorzata and Ślężak, Jan and Kosmalska, Izabela and Rymarczyk, Marta and Wilkowska, Klaudia and Jacczak, Barbara and Totoń, Ewa and Lisiak, Natalia and Kopczyński, Przemysław and Rubiś, Błażej},
  title = {Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells—A Preliminary Study},
  journal = {Genes},
  year = {2023},
  volume = {14},
  number = {3},
  pages = {702},
  doi = {10.3390/genes14030702}
}
Kostenlos starten →